To: Endoworld Hospital

#723,Infront of Airport,

Chikalthana, Aurangabad

MAHARASHTRA

Aurangabad - 431007

Contact: 7045919305

Report Of: Mrs. SAVITA PAWARA

Pt. Contact:



Sample ID	2300116435
Patient ID	1002356125
Collected on	17/07/2023
Received on	19/07/2023 16:20
Registered on	19/07/2023 15:17
Reported on	20/07/2023 09:24
Referred by	DR.RINKU PALASKAR

Hemoglobinopathy Screening

Patient Name: Mrs. SAVITA PAWARA	Sample Type: Whole Blood EDTA	<u> </u>
Date of Birth/Age: 02/05/1994	Gender: FEMALE	City: AURANGABAD
Method: High Performance Liquid Chromatography (HPLC)	Blood Transfusion History: No	
Referral Reason or Clinical History:		

About the test

Hemoglobinopathy screening by high performance liquid chromatography is a blood test that is used for detecting quantitative and qualitative abnormalities of hemoglobin (Hb), namely, Thalassemia and Structural Hb variants (e.g. HbS) respectively. The test helps identify individuals with these disorders so that they can receive timely and appropriate treatment and care. Antenatal diagnosis of these disorders allows measures to reduce the chances of the birth of an affected baby. It is also possible to screen the newborns for hemoglobinopathies using this approach, thereby decreasing the mortality & morbidity associated with conditions like Sickle cell disorder.

Test findings				
Hb Fraction	Observed Value (%)	Expected Value (%)		
HbF	0.5%	<2%		
P2*	3.7%	<4.6%		
HbA0	87.6%	85 - 95%		
HbA2/HbE	2.9%	1.8 - 3.5%		
HbD	Absent	Absent		
HbS	Absent	Absent		

^{*}The mentioned P2 value from BioRad Variant-II HPLC system is equivalent of HbA1c value in BioRad D10 system

Interpretation

Chromatogram shows normal hemoglobin pattern.

Hemoglobin and PCV are reduced, RBC count is incressed and red cell indices are microcytic with high RDW. These findings suggest the following possibilities

- 1. Alpha thallsemia trait
- 2. Silent beta thallsemia trait

Suggestions

- 1. Mollecular studies to rule aot the above possibilites.
- 2. Haemoglobin analysis of the parentes and the partner by HPLC.

Verified by **Mr. Pradip Kadam** Incharge Biochemistry

Bede

Dr. A. Dasgupta MD, PhD,
Consultant Hematopathologist

Page 1

of **2**

HPLC Findings

Patient Data
Sample ID:
Patient ID:
Name:
Physician:
Sex:
DOB:

Comments:

Analysis Data
Analysis Performed:
Injection Number:
Run Number:
Rack ID:
Tube Number:

07/19/2023 13:39:15 3964 323

Tube Number: 8
Report Generated: 07/19/2023 15:06:50
Operator ID:

0002

	Calibrated		Retention	Peak
Peak Name	Area %	Area %	Time (min)	Area
Unknown		0.1	1.00	1435
F	0.5		1.09	10690
Unknown		0.8	1.22	15631
P2		3.7	1.30	76551
P3		4.3	1.69	88806
Ao		87.6	2.35	1797255
A2	2.9		3.61	61892

Total Area: 2,052,260

45.0 37.5 30.0 22.5 15.0 7.5 0.0 12.3 15.0 15

Analysis comments:

F Concentration = 0.5 % A2 Concentration = 2.9 %

L	mpor	tant B	lood Ir	ndices (from	CBC A	Analysis)	

·		•	
Parameters	Result	Reference Range	Units
Hemoglobin (Hb)	11.78 🛕	12 - 15	g/dL
RBC Count	5.23 🗥	3.8 - 4.8	x 10 ⁶ /μL
Hematocrit	34.90 🗥	36 - 46	%
Mean Corpuscular Volume (MCV)	66.70 ▲	83 - 101	fL
Mean Corpuscular Hb (MCH)	22.50 🗥	27 - 32	pg
Mean Corpuscular Hb Conc. (MCHC)	33.80	31.5 - 34.5	g/dL
RBC Distribution Width (RDW) (CV)	21.60 🛕	11.6 - 14	%
RBC Distribution Width (RDW) (SD)	42.80	39 - 46	fL

Notes:

- 1. Recent blood transfusions and iron deficiency can interfere with the results, repeat testing is recommended three months after the last blood transfusion. In case of iron deficiency, it is recommended to evaluate the result post-correction of iron deficiency.
- 2. Megaloblastic anemia can cause elevated HbA2 levels. A repeat assay is recommended after correction of VitB12 deficiency.
- 3. Mild to moderately elevated fetal hemoglobin (HbF) values are observed during pregnancy, hypoxia, chronic kidney disease, use of certain drugs,myelodysplastic syndromes (MDS), aplastic anemia and conditions of stress hemopoiesis.
- 4. Cases with borderline HbA2 levels (3.1-3.9%) could represent Silent Beta-thalassemia trait, or co-existent iron deficiency or Alpha-thalassemia in a case of Beta-thalassemia trait. They need to be investigated further by appropriate tests.
- 5. Confirmatory molecular tests for Beta-thalassemia traits and abnormal hemoglobin disorders (e.g. HbS, HbE, and HbD), followed by subsequent prenatal diagnosis (If required) are available at our centre.
- 6. The mentioned P2 value from BioRad Variant-II HPLC system is equivalent of HbA1c value in BioRad D10 system

Disclaimers:

- 1. The Hb-HPLC is a screening test that detects Beta-thalassemia and other hemoglobin variants. It does not identify Alpha-thalassemia and Silent Beta-thal-assemia carriers. DNA analysis is recommended to rule out Alpha-thalassemia and Silent Beta-thalassemia carriers.
- 2. The result must be interpreted in conjunction with the complete blood counts (CBC), VitB12 and iron profile of the individual.
- 3. Each sample received at Lilac Insights' processing centre is handled with the utmost sensitivity and care. All samples received on Sundays and National holidays are stored as per specific guidelines for the respective specimens and processed on the next day.
- 4. P2 peak in Bio Rad's Variant II HPLC platform represents glycated hemoglobin. It is elevated in uncontrolled diabetes.

Verified by

Verified by

Mr. Pradip Kadam
Incharge Biochemistry

Dr. A. Dasgupta MD, PhD,
Consultant Hematopathologist

Dr. A. Dasgupta MD, PhD,

Page 2 of 2